Boehringer Ingelheim begins trials for ‘Viagra for women’

Share this article:
Boehringer Ingelheim has begun trials on a sex drug that has been dubbed a “Viagra for women,” because it works directly on the pleasure zones of the female brain to restore low libido. The drug, known as flibanserin, was originally tested as an anti-depressant. Participants in those trials reported that while their depression was no better, they had experienced a boost in sexual desire. Boehringer is reportedly conducting four trials on 5,000 women in 220 locations and is hoping to receive approval from the FDA in 2009. Boehringer’s medical director for the UK, Dr. Charles de Wet, told the British newspaper The Times that “no excessive sexual side effects have been reported from the treatment in any clinical trial.” Flibanserin takes several weeks for a significant effect to build up in the brain, meaning that, unlike Viagra, it cannot be “popped” in advance of an evening out.
Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.